Form 4: Harvard Bioscience CEO Forfeits Performance-Based Restricted Stock Units

James W. Green, CEO of Harvard Bioscience, forfeited 145,365 performance-based restricted stock units on December 31, 2024, following the final determination of applicable performance conditions.

Summary

• On December 31, 2024, James W. Green, the CEO of Harvard Bioscience, forfeited 145,365 performance-based restricted stock units (RSUs).
• The forfeiture was due to the final determination of the applicable performance conditions for these RSUs, which were initially granted on March 1, 2022.
• Following this transaction, Green directly owns 2,883,501 shares of Harvard Bioscience common stock.
• This total includes 117,713 RSUs vesting on December 29, 2025, 214,797 RSUs vesting in equal installments on March 19 of 2025, 2026, and 2027, 554,407 RSUs with performance-based vesting conditions, and 1,996,584 shares of common stock.

Sentiment

Score: 4

Explanation: The forfeiture of performance-based RSUs is a negative signal, suggesting that the company did not achieve certain performance goals. However, it's a single event and doesn't necessarily indicate a long-term negative trend.

Negatives

• The CEO forfeited 145,365 performance-based RSUs, indicating that the performance conditions were not met.

Risks

• The forfeiture of performance-based RSUs may signal concerns about the company's ability to meet its performance targets.

Industry Context

Form 4 filings are standard disclosures for insiders, but the forfeiture of performance-based RSUs can be a signal to the market regarding the company's performance against its targets.

Stakeholder Impact

• Shareholders may be concerned about the company's ability to meet performance targets, as indicated by the forfeiture of RSUs.

Key Dates